Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

Summit Therapeutics PLC (NASDAQ:SMMT) shares gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $14.98, but opened at $13.72. Summit Therapeutics shares last traded at $13.5480, with a volume of 1,571,258 shares traded.

The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Key Headlines Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Summit reported updated Phase III survival data for its HARMONi lung cancer study and said its lead drug ivonescimab continues to advance, including new development collaborations that broaden its pipeline optionality. Article Title
• Positive Sentiment: Unusually heavy options activity, with call volume far above normal, suggests traders are positioning for a possible rebound or additional catalyst-driven upside.
• Neutral Sentiment: The company’s Q2 earnings call and presentation focused on clinical and operational progress, keeping attention on future data readouts rather than near-term revenue generation. Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a neutral rating, reinforcing that analysts remain cautious while waiting for clearer evidence that ivonescimab can deliver commercially meaningful results. Article Title
• Negative Sentiment: Summit posted a wider-than-expected Q2 loss with no revenue, highlighting continued cash burn and reliance on future clinical success to justify its valuation. Article Title
• Negative Sentiment: An article noted that analyst expectations were being tempered after the initial lung cancer survival data, which may be pressuring sentiment and contributing to the stock’s recent weakness. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SMMT shares. Citigroup started coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating on the stock. KeyCorp reissued an “overweight” rating on shares of Summit Therapeutics in a research note on Monday, June 1st. Piper Sandler lowered their price objective on shares of Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Friday, May 1st. Jefferies Financial Group set a $15.00 price objective on Summit Therapeutics in a research report on Friday. Finally, Stifel Nicolaus reduced their target price on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics has an average rating of “Hold” and an average target price of $26.15.

Insider Buying and Selling at Summit Therapeutics

In other Summit Therapeutics news, CFO Manmeet Singh Soni bought 50,000 shares of Summit Therapeutics stock in a transaction dated Thursday, June 4th. The shares were purchased at an average cost of $14.45 per share, with a total value of $722,500.00. Following the transaction, the chief financial officer directly owned 3,123,603 shares of the company’s stock, valued at $45,136,063.35. This represents a 1.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert W. Duggan purchased 3,810,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the purchase, the chief executive officer owned 573,883,879 shares in the company, valued at $7,529,356,492.48. This represents a 0.67% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 7,870,000 shares of company stock valued at $103,616,900. 83.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Summit Therapeutics

Several hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its holdings in Summit Therapeutics by 5.0% in the first quarter. AQR Capital Management LLC now owns 65,623 shares of the company’s stock worth $1,266,000 after purchasing an additional 3,134 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Summit Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after purchasing an additional 694 shares during the last quarter. Creative Planning boosted its position in shares of Summit Therapeutics by 6.7% in the 2nd quarter. Creative Planning now owns 21,390 shares of the company’s stock worth $455,000 after purchasing an additional 1,336 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Summit Therapeutics by 33.8% in the 2nd quarter. Legal & General Group Plc now owns 26,367 shares of the company’s stock worth $561,000 after purchasing an additional 6,662 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Summit Therapeutics in the 2nd quarter worth approximately $132,000. Institutional investors own 4.61% of the company’s stock.

Summit Therapeutics Trading Down 8.8%

The company has a market cap of $10.60 billion, a PE ratio of -12.20 and a beta of -1.26. The firm has a 50 day moving average of $15.03 and a two-hundred day moving average of $16.68.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.